Microfluidic Platelet Production Under Shear Without Membrane Clogging
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing bioreactor designs for ex vivo platelet production are inefficient for rapid large-scale production due to clogging issues and limited production rates, and the effect of pharmacological substances on megakaryocytes under shear stress conditions has not been observed in prior art.
Innovation Solution
An ex vivo method involving a fluidic device with non-porous channels and shear stress, combined with megakaryocyte modulator compounds like Rho/ROCK inhibitors, nicotinamide, blebbistatin, latrunculin, and GM6001, to enhance platelet production by increasing megakaryocyte ploidy and cytoskeleton organization.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If porous membrane systems are used for megakaryocyte passage, then platelet production is enabled, but production rate is limited due to clogging and cell trapping
Solution Approach 1:
The device segments the flow path into multiple parallel channels, distributing megakaryocytes across numerous flow paths. This prevents clogging in any single channel while maintaining continuous cell passage and platelet production across the entire system.
Solution Approach 2:
The invention transitions from two-dimensional porous membrane passage to three-dimensional flow-through channels with obstacles. Megakaryocytes are captured on channel walls and obstacles rather than passing through membranes, enabling continuous circulation and repeated platelet shedding without clogging.
2Productivity
If limited number of slits are provided for megakaryocyte passage, then device structure is simplified, but production speed is limited due to cell trapping in reservoir
Solution Approach 1:
The channel structure is segmented into multiple regions with obstacles distributed along the flow path. This creates numerous capture sites for megakaryocytes throughout the channel, preventing accumulation and trapping in reservoir areas while maintaining continuous production.
Solution Approach 2:
The design enables continuous circulation of megakaryocytes through the channels, with repeated capture and release cycles. This continuous action prevents cell trapping and maintains sustained platelet production rates without requiring complex multi-reservoir systems.
3Quantity of substance
If pharmacological substances are added during culture stage, then polyploidization is enhanced, but no additional effect is observed during perfusion under shear stress
Solution Approach 1:
Megakaryocytes are pre-treated with pharmacological substances during the culture stage to achieve optimal polyploidization and maturation before perfusion. This preliminary preparation ensures cells are ready for efficient platelet shedding during subsequent shear stress application, maximizing platelet yield without requiring substances during perfusion.
Solution Approach 2:
The protocol uses periodic application of pharmacological substances at specific culture time points to synchronize megakaryocyte maturation. This timing strategy ensures optimal cell state before perfusion, where shear stress alone drives platelet production without needing additional chemical agents.
4Ease of operation
If megakaryocytes are pushed through slits with limited availability, then device structure is simplified, but many cells remain stuck in reservoir
Solution Approach 1:
The flow path is segmented into multiple channels with distributed obstacles, providing numerous passage points for megakaryocytes. This prevents cell accumulation in reservoir areas and ensures continuous flow through the system, maximizing the number of productive cells.
Solution Approach 2:
Obstacles in the channels act as intermediaries that temporarily capture and release megakaryocytes, facilitating their passage through the device. This intermediary mechanism prevents permanent cell trapping while maintaining continuous cell flow and platelet production.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Significantly improves platelet yield and quality by enhancing platelet release under shear stress conditions, mimicking natural bone marrow environments, and producing platelets that resemble human platelets more closely.
Implementation Method 1
subjecting said suspension of cells in the channel to a flow having a shear rate suitable for elongation and fragmentation of the megakaryocyte and platelet release
Data Source
Figure 1A~1B
Figure 2A~2B
Figure 3
AI summary
The present invention relates to an ex vivo method for producing platelets including a combination of use of pharmacological substances and microfluidic device features, for high yield and high quality platelet production from megakaryocytes or their progenitors.